Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Everitt

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|July 22, 1998
Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressureJ R Piltz, R A Stone, S Boike, et al.
The Journal of Infectious Diseases|September 1, 1996
The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteersD E Everitt, C B Davis, K Thompson, et al.
The New England Journal of Medicine|July 16, 1992
A randomized trial of a program to reduce the use of psychoactive drugs in nursing homesJ Avorn, S B Soumerai, D E Everitt, et al.
The Journal of Rheumatology|April 4, 2006
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritisRené Westhovens, Frédéric Houssiau, Johan Joly, et al.
Current Medical Research and Opinion|May 24, 2007
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasisAlice B Gottlieb, Kevin D Cooper, Thomas S McCormick, et al.
Journal of Clinical Pharmacology|November 1, 1994
Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteersM I Freed, P R Audet, N Zariffa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasisEiko Toichi, Gisela Torres, Thomas S McCormick, et al.
The Journal of Investigative Dermatology|December 22, 2004
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasisCatharine L Kauffman, Nancy Aria, Eiko Toichi, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1999
Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV diseaseH C Meissner, J R Groothuis, W J Rodriguez, et al.
Journal of Clinical Pharmacology|February 27, 2007
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritisHonghui Zhou, Haishan Jang, Roy M Fleischmann, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|July 22, 1998
Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressureJ R Piltz, R A Stone, S Boike, et al.
The Journal of Infectious Diseases|September 1, 1996
The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteersD E Everitt, C B Davis, K Thompson, et al.
The New England Journal of Medicine|July 16, 1992
A randomized trial of a program to reduce the use of psychoactive drugs in nursing homesJ Avorn, S B Soumerai, D E Everitt, et al.
The Journal of Rheumatology|April 4, 2006
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritisRené Westhovens, Frédéric Houssiau, Johan Joly, et al.
Current Medical Research and Opinion|May 24, 2007
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasisAlice B Gottlieb, Kevin D Cooper, Thomas S McCormick, et al.
Journal of Clinical Pharmacology|November 1, 1994
Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteersM I Freed, P R Audet, N Zariffa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasisEiko Toichi, Gisela Torres, Thomas S McCormick, et al.
The Journal of Investigative Dermatology|December 22, 2004
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasisCatharine L Kauffman, Nancy Aria, Eiko Toichi, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1999
Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV diseaseH C Meissner, J R Groothuis, W J Rodriguez, et al.
Journal of Clinical Pharmacology|February 27, 2007
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritisHonghui Zhou, Haishan Jang, Roy M Fleischmann, et al.
Pageof 9